Network-based approaches elucidate differences within APOBEC and clock-like signatures in breast cancer.

APOBEC Breast cancer Clock-like signatures Continuous cancer phenotype Gene network Mutational signature Network-phenotype association

Journal

Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844

Informations de publication

Date de publication:
29 05 2020
Historique:
received: 11 03 2020
accepted: 07 05 2020
entrez: 31 5 2020
pubmed: 31 5 2020
medline: 14 5 2021
Statut: epublish

Résumé

Studies of cancer mutations have typically focused on identifying cancer driving mutations that confer growth advantage to cancer cells. However, cancer genomes accumulate a large number of passenger somatic mutations resulting from various endogenous and exogenous causes, including normal DNA damage and repair processes or cancer-related aberrations of DNA maintenance machinery as well as mutations triggered by carcinogenic exposures. Different mutagenic processes often produce characteristic mutational patterns called mutational signatures. Identifying mutagenic processes underlying mutational signatures shaping a cancer genome is an important step towards understanding tumorigenesis. To investigate the genetic aberrations associated with mutational signatures, we took a network-based approach considering mutational signatures as cancer phenotypes. Specifically, our analysis aims to answer the following two complementary questions: (i) what are functional pathways whose gene expression activities correlate with the strengths of mutational signatures, and (ii) are there pathways whose genetic alterations might have led to specific mutational signatures? To identify mutated pathways, we adopted a recently developed optimization method based on integer linear programming. Analyzing a breast cancer dataset, we identified pathways associated with mutational signatures on both expression and mutation levels. Our analysis captured important differences in the etiology of the APOBEC-related signatures and the two clock-like signatures. In particular, it revealed that clustered and dispersed APOBEC mutations may be caused by different mutagenic processes. In addition, our analysis elucidated differences between two age-related signatures-one of the signatures is correlated with the expression of cell cycle genes while the other has no such correlation but shows patterns consistent with the exposure to environmental/external processes. This work investigated, for the first time, a network-level association of mutational signatures and dysregulated pathways. The identified pathways and subnetworks provide novel insights into mutagenic processes that the cancer genomes might have undergone and important clues for developing personalized drug therapies.

Sections du résumé

BACKGROUND
Studies of cancer mutations have typically focused on identifying cancer driving mutations that confer growth advantage to cancer cells. However, cancer genomes accumulate a large number of passenger somatic mutations resulting from various endogenous and exogenous causes, including normal DNA damage and repair processes or cancer-related aberrations of DNA maintenance machinery as well as mutations triggered by carcinogenic exposures. Different mutagenic processes often produce characteristic mutational patterns called mutational signatures. Identifying mutagenic processes underlying mutational signatures shaping a cancer genome is an important step towards understanding tumorigenesis.
METHODS
To investigate the genetic aberrations associated with mutational signatures, we took a network-based approach considering mutational signatures as cancer phenotypes. Specifically, our analysis aims to answer the following two complementary questions: (i) what are functional pathways whose gene expression activities correlate with the strengths of mutational signatures, and (ii) are there pathways whose genetic alterations might have led to specific mutational signatures? To identify mutated pathways, we adopted a recently developed optimization method based on integer linear programming.
RESULTS
Analyzing a breast cancer dataset, we identified pathways associated with mutational signatures on both expression and mutation levels. Our analysis captured important differences in the etiology of the APOBEC-related signatures and the two clock-like signatures. In particular, it revealed that clustered and dispersed APOBEC mutations may be caused by different mutagenic processes. In addition, our analysis elucidated differences between two age-related signatures-one of the signatures is correlated with the expression of cell cycle genes while the other has no such correlation but shows patterns consistent with the exposure to environmental/external processes.
CONCLUSIONS
This work investigated, for the first time, a network-level association of mutational signatures and dysregulated pathways. The identified pathways and subnetworks provide novel insights into mutagenic processes that the cancer genomes might have undergone and important clues for developing personalized drug therapies.

Identifiants

pubmed: 32471470
doi: 10.1186/s13073-020-00745-2
pii: 10.1186/s13073-020-00745-2
pmc: PMC7260830
doi:

Substances chimiques

APOBEC Deaminases EC 3.5.4.5

Types de publication

Journal Article Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

52

Références

Genome Biol. 2015 Aug 08;16:160
pubmed: 26253137
Bioinformatics. 2018 Jan 15;34(2):330-337
pubmed: 29028923
Cell Rep. 2013 Jan 31;3(1):246-59
pubmed: 23318258
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Nat Commun. 2018 Aug 17;9(1):3292
pubmed: 30120226
Cell. 2017 Jul 27;170(3):534-547.e23
pubmed: 28753428
Nucleic Acids Res. 2017 Jul 3;45(W1):W514-W522
pubmed: 28472504
EBioMedicine. 2017 Jun;20:39-49
pubmed: 28551381
Pac Symp Biocomput. 2013;:135-46
pubmed: 23424119
PLoS Genet. 2018 Nov 9;14(11):e1007779
pubmed: 30412573
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110
Nat Genet. 2014 May;46(5):487-91
pubmed: 24728294
Nat Methods. 2013 Nov;10(11):1108-15
pubmed: 24037242
Cancer Res. 2017 Sep 1;77(17):4567-4578
pubmed: 28698210
Oncotarget. 2016 Apr 26;7(17):23312-21
pubmed: 27004405
Nat Commun. 2016 May 02;7:11383
pubmed: 27136393
Cancer Lett. 2008 Nov 28;271(2):272-80
pubmed: 18662849
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Med Genet. 2007 Nov;44(11):726-31
pubmed: 17660459
Genome Res. 2016 Feb;26(2):174-82
pubmed: 26755635
Bioinformatics. 2015 Jun 15;31(12):i284-92
pubmed: 26072494
Cell Rep. 2018 Oct 16;25(3):702-714.e6
pubmed: 30332649
Oncogene. 2008 Aug 21;27(36):4888-99
pubmed: 18454178
Sci Rep. 2018 May 8;8(1):7205
pubmed: 29739984
Science. 2016 Nov 4;354(6312):618-622
pubmed: 27811275
Cancer Res. 2013 Dec 15;73(24):7222-31
pubmed: 24154874
Nat Genet. 2015 Dec;47(12):1402-7
pubmed: 26551669
Pac Symp Biocomput. 2012;:55-66
pubmed: 22174262
Oncogene. 2015 Jul 30;34(31):4118-29
pubmed: 25347740
J Mol Cell Biol. 2014 Dec;6(6):442-57
pubmed: 25404613
Antioxid Redox Signal. 2013 Jun 20;18(18):2409-19
pubmed: 23216312
Genome Biol. 2013 Apr 29;14(4):R39
pubmed: 23628380
Pac Symp Biocomput. 2020;25:262-273
pubmed: 31797602
Genome Biol. 2016 Sep 30;17(1):202
pubmed: 27716362
Biochem Biophys Rep. 2018 Oct 30;16:115-121
pubmed: 30417129
Fam Cancer. 2016 Apr;15(2):215-9
pubmed: 26759166
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10469-74
pubmed: 11517304
Nat Genet. 2016 Jun;48(6):600-606
pubmed: 27111033
Cell Rep. 2018 Apr 03;23(1):239-254.e6
pubmed: 29617664
PLoS Comput Biol. 2016 Mar 10;12(3):e1004747
pubmed: 26963104
Breast Cancer Res. 2011;13(6):R119
pubmed: 22114986
PLoS Comput Biol. 2017 Oct 12;13(10):e1005695
pubmed: 29023534
Curr Opin Genet Dev. 2014 Feb;24:52-60
pubmed: 24657537
Nucleic Acids Res. 2017 Nov 2;45(19):11056-11069
pubmed: 28977491
Mol Syst Biol. 2007;3:140
pubmed: 17940530
JAMA Oncol. 2015 Apr;1(1):23-32
pubmed: 26182300
Cell. 2013 Mar 28;153(1):17-37
pubmed: 23540688
Genome Med. 2019 Jul 26;11(1):49
pubmed: 31349863
Nat Cell Biol. 2001 Apr;3(4):433-8
pubmed: 11283620
Nat Genet. 2002 May;31(1):55-9
pubmed: 11967536
Cell Cycle. 2016;15(7):998-1008
pubmed: 26918916
Oncogene. 2018 Jul;37(29):3924-3936
pubmed: 29695832
Bioinformatics. 2017 Mar 15;33(6):814-821
pubmed: 27153670
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nat Commun. 2018 May 10;9(1):1857
pubmed: 29748584
Oncogene. 2008 Sep 18;27(41):5527-41
pubmed: 18794886
Nat Genet. 2017 Oct;49(10):1476-1486
pubmed: 28825726
Bioinformatics. 2016 Apr 1;32(7):968-75
pubmed: 26163509
Nat Genet. 2013 Sep;45(9):977-83
pubmed: 23852168
Nat Rev Genet. 2014 Sep;15(9):585-98
pubmed: 24981601
JAMA. 2007 Jun 6;297(21):2360-72
pubmed: 17545690
Curr Protoc Bioinformatics. 2013 Mar;Chapter 8:Unit 8.17
pubmed: 23504936

Auteurs

Yoo-Ah Kim (YA)

National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, 8600 Rockville Pike, Bethesda, 20894, USA.

Damian Wojtowicz (D)

National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, 8600 Rockville Pike, Bethesda, 20894, USA.

Rebecca Sarto Basso (R)

National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, 8600 Rockville Pike, Bethesda, 20894, USA.
Department of Industrial Engineering and Operations Research, University of California, Berkeley, 94720, CA, USA.

Itay Sason (I)

School of Computer Science, Tel Aviv University, Tel Aviv, 69978, Israel.

Welles Robinson (W)

Center for Bioinformatics and Computational Biology, University of Maryland, 8314 Paint Branch Dr, College Park, 20742, USA.

Dorit S Hochbaum (DS)

Department of Industrial Engineering and Operations Research, University of California, Berkeley, 94720, CA, USA.

Mark D M Leiserson (MDM)

Center for Bioinformatics and Computational Biology, University of Maryland, 8314 Paint Branch Dr, College Park, 20742, USA.

Roded Sharan (R)

School of Computer Science, Tel Aviv University, Tel Aviv, 69978, Israel.

Fabio Vadin (F)

Department of Information Engineering, University of Padova, Via Gradenigo 6/A, Padua, I-35131, Italy.

Teresa M Przytycka (TM)

National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, 8600 Rockville Pike, Bethesda, 20894, USA. przytyck@ncbi.nlm.nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH